Milestones

2018

On July 17 2018, Green Valley announced that GV-971 met the primary endpoint in the phase III clinical trial.

2018

Established a US-based artificial intelligence team led by senior scientist from Banner Alzheimer 's Institute (BAI), to create a precise diagnosis and treatment platform for brain diseases.

2017

Completed patient enrollment for Phase III clinical trial study of the 971 Project. The speed of patient enrollment broke the record of international clinical studies on Alzheimer's disease.

2017

Green Valley set up the Expert Academician Workstation and the Shenyang Pharmaceutical University Graduate and Postgraduate Student Practice Base, so as to speed up the platform construction of China’s innovative medicine development by integrating intellectual resource from leading scientists and universities.

2016

Initiated cooperation with Shanghai Brain Health Foundation, and launched a 30-year senile brain health cohort study covering 100,000 people, aiming to promote development of brain disease study through digging out key risk factors of Alzheimer's disease and other brain diseases

2015

Signed long-term strategic partnership with Quintiles, the world's largest biopharmaceutical development and business outsourcing service provider, to carry out close cooperation in clinical research worldwide.

2015

Signed strategic cooperation agreement with Shenyang Pharmaceutical University to establish systematic and long-term strategic cooperation in talent training, transformation of scientific and technological achievements, etc.

2014

Inaugurated Green Valley (Benxi) Biopharmaceutical Industrial Base, with aiming to build a research and manufacturing site of carbohydrate drugs.

2013

Completed 971 clinical trial study (Phase II)

2010

Salvianolate entered into NRDL.

2009

Green Valley acquired the 971 Project.

2006

Established “Green Valley Innovation Fund” at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, for research and development of China’s innovative drugs.

2005

Established Green Valley Research Institute in cooperation with Shanghai Institutes for Biological Sciences and Shanghai Institute of Materia Medica, Chinese Academy of Sciences.

2005

Salvianolate injection received SFDA approval.

2004

built up the manufacturing site called ‘Green Valley Life Park’.

2000

Restructured Green Valley Group and established Shanghai Green Valley Pharmaceutical Co., Ltd., in cooperation with the Shanghai Institute of Materia Medica